Allogene Therapeutics, Inc. (ALLO)

In the past six months, Allogene Therapeutics reported its second and third-quarter 2025 financial results and provided business updates. The company participated in several investor conferences. Allogene announced an ALPHA3 Trial-in-Progress Poster Presentation at the ASH Annual Meeting. Allogene reported a favorable result for Servier in arbitration with Cellectis, granting Allogene full development and commercial control of cemacabtagene ansegedleucel. Allogene Therapeutics positioned 2026 as a "program-defining year" for scalable, real-world allogeneic CAR T, anticipating a first-half 2026 catalyst stack. The stock trended up by 15.44% following promising clinical trial results and positive analyst sentiment, with UBS initiating coverage with a "Buy" rating and an $8 price target, and Citizens upgrading to "Outperform" with a $5 price target. The stock price decreased by 1.8% on January 13, 2026.

As a clinical-stage biotechnology company, Allogene Therapeutics, Inc. does not have marketed products that generate significant revenue, and therefore, the concept of traditional "demand seasonality" for products and services does not directly apply. Historically, buying Allogene Therapeutics Inc (ALLO) stock in February has had the highest probability of a positive return (71.43%), while December has shown the lowest probability (12.50%).

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company's core focus is on creating "off-the-shelf" AlloCAR T™ products, designed to be readily available for a broad patient population, overcoming the complexities of patient-specific autologous CAR T therapies. Its pipeline includes product candidates like Cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma and chronic lymphocytic leukemia, ALLO-316 for advanced renal cell carcinoma, and ALLO-329 for autoimmune diseases. Other clinical-stage products target multiple myeloma, small cell lung cancer, gastric and pancreatic cancer, and acute myeloid leukemia.

Allogene Therapeutics' primary operations are based in the United States, with its headquarters in South San Francisco, California, and additional offices in Los Angeles, California, and a manufacturing facility in Newark, California. The company's global presence is characterized by multi-center clinical trials across North America, Europe, and potentially other regions, as well as global collaborations for research and technology access.

Allogene Therapeutics has maintained a generally positive brand reputation, particularly within the biotech and investment communities. UBS initiated coverage with a "Buy" rating and an $8 price target, while Citizens upgraded the company to "Outperform" with a $5 price target. A favorable arbitration result for Servier in December 2025 granted Allogene full development and commercial control of its lead candidate, cemacabtagene ansegedleucel. The company has positioned 2026 as a "program-defining year" with several pivotal clinical readouts expected for its allogeneic CAR T-cell therapies.

Allogene Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. The company has 309 institutional owners and shareholders holding a total of 186,934,953 shares. Major institutional owners include Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., Citadel Advisors LLC, and Vanguard Group Inc. Pfizer Inc is noted as the largest individual shareholder, owning 9.80% of the company. Arie Belldegrun is also identified as owning the most shares among individual investors.